ArticlePLOS mental health2025
Perspectives and experiences with sleep and recovery among women receiving buprenorphine for opioid use disorder.
Article in PLOS mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Sleep issues are prevalent among women receiving medication for opioid use disorder (OUD). However, there is limited data about subjective sleep experiences and how they relate to OUD trajectories. This mixed-methods study explored the intersection of sleep and OUD recovery from the patient perspective among a sample of women receiving medication for OUD. This study enrolled non-pregnant women aged 18-65 who were stabilized on buprenorphine from an outpatient OUD program. Participants were recruited during their routine treatment visits, and enrollment occurred from February 2022 through September 2023. Study participants who endorsed clinically elevated insomnia symptoms on the Insomnia Severity Index (ISI) (≥11 score) (n=50) were included in current study analyses. A sub-sample (n=11) who met the ISI threshold participated in semi-structured interviews. Survey responses were analyzed using descriptive statistics, and interviews were analyzed using applied thematic analysis. The average length of time on buprenorphine for the overall sample was 30 months (range: 2 months - 245 months). Participants reported engagement in healthy sleep behaviors, grouped into four domains: positive sleep related cognitions, sleep environment, sleep restriction, and reducing stimulating activities. Respondents characterized the multidimensional relationship between sleep and health. Women also described how sleep evolves through addiction into recovery, and how good sleep reduces risk of return to substance use. Finally, women discussed the impacts that medication for OUD have on sleep, specifically how they might time their buprenorphine to align with sleep and how it might impact their energy levels. We found that sleep is a dynamic process among this sample of women receiving medication for OUD. Findings are intended to inform future investigations of the mechanisms underlying the sleep-OUD intersection. In addition, this study reflects the importance of incorporating patient perspectives into the development of therapeutics targeting this patient population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.